Theralase Technologies Stock Return On Equity
| TTX Stock | 0.14 0.01 6.67% |
Theralase Technologies fundamentals help investors to digest information that contributes to Theralase Technologies' financial success or failures. It also enables traders to predict the movement of Theralase Stock. The fundamental analysis module provides a way to measure Theralase Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Theralase Technologies stock.
Theralase |
Theralase Technologies Company Return On Equity Analysis
Theralase Technologies' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Theralase Technologies has a Return On Equity of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Return On Equity (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Theralase Fundamentals
| Current Valuation | 47.58 M | |||
| Price To Book | 25.99 X | |||
| Price To Sales | 69.51 X | |||
| Revenue | 780.64 K | |||
| EBITDA | (4.13 M) | |||
| Net Income | (4.41 M) | |||
| Cash Flow From Operations | (4.03 M) | |||
| Market Capitalization | 47.68 M | |||
| Total Asset | 5.94 M | |||
| Net Asset | 5.94 M |
About Theralase Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theralase Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theralase Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theralase Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Theralase Stock Analysis
When running Theralase Technologies' price analysis, check to measure Theralase Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theralase Technologies is operating at the current time. Most of Theralase Technologies' value examination focuses on studying past and present price action to predict the probability of Theralase Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theralase Technologies' price. Additionally, you may evaluate how the addition of Theralase Technologies to your portfolios can decrease your overall portfolio volatility.